期刊文献+

原发性双侧乳腺癌35例

原文传递
导出
摘要 目的探讨原发性双侧乳腺癌(简称双乳癌)的临床病理特征。方法回顾性分析35例原发性双乳癌患者(同时性双乳癌12例,异时性双乳癌23例)的临床病理资料。结果与同时性双乳癌比较,异时性双乳癌首发癌年龄早(中位年龄,43岁:51岁)。中位随访38个月(6个月~10年),全组共出现11例局部复发,14例远处转移(8例肺转移,5例骨转移,1例肝转移),9例死亡。异时性双乳癌复发、转移患者所占比例高(复发:43.5%:8.3%,转移:52.2%:16.7%)(10=0.034、P=0.042)。全组8例为三阴性双乳癌,占22.9%,其中5例(62.5%)出现局部复发,6例(75%)出现远处转移,与非三阴性双乳癌相比,三阴性双乳癌复发、转移患者所占比例高(复发:62.5%:22.2%,转移:75%:29.6%)(P=0.031、P=0.021)。结论与同时性双乳癌比较,异时性双乳癌首发癌年龄早,预后差。三阴性双乳癌在双乳癌中所占比例高,预后较非三阴性者差。
作者 郑进 赵魁
出处 《肿瘤研究与临床》 CAS 2011年第5期344-346,共3页 Cancer Research and Clinic
关键词 乳腺肿瘤 预后
  • 相关文献

参考文献14

  • 1Robbins GF, Berg JW. Bilateral primary breast cancer.'a prospective clinicopathological study. Cancer, 1964, 12: 1501-1527.
  • 2Hartman M, Czene K, Reilly M, et al. Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J Clin Oncol, 2007, 25: 4210-4216.
  • 3Kuo WH, Yen AM, Lee PH, et al. Cumulative survival in early-onset unilateral and bilateral breast cancer: an analysis of 1907 Taiwan Residents women. BrJ Cancer, 2009, 100: 563-570.
  • 4Lv ML, Zhang S, Liu H, et al. Her-2 and hormone receptor status in bilateral primary breast cancer and their association with prognosis. Chin J Breast Dis (Electronic Edition),2009, 3: 32-40.
  • 5Borg A, Halle RW, Malone KE, et al. Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study. Hum Mutat, 2010, 31: 1200-1240.
  • 6Diez O, Guti-rrez-Enriquez S, Mediano C, et al. A novel de novo BRCA2 mutation of paternal origin identified in a Spanish woman with early onset bilateral breast cancer. Breast Cancer Res Treat, 2010, 121: 221-225.
  • 7Edwards E, Yearwood C, Silliboume J, et al. Identification of a de novo BRCA1 mutation in a woman with early onset bilateral breast cancer. Faro Cancer, 2009, 4: 479-482.
  • 8Skasko E, Kluska A, Niwinska A, et al. Age at onset of bilateral breast cancer, the presence of hereditary BRCA1, BRCA2, CHEK2 gene mutations and positive family history of cancer. Onkologie, 20(19, 32: 182-188.
  • 9Evans DG, Ahmed M, Bayliss S, et al. BRCA1, BRCA2 and CHEK2 c.1100 delC mutations in patients with double primaries of the breasts and/or ovaries. J Med Genet, 2010, 47: 561-566.
  • 10Huo D, Melkonian S, Rathouz PJ, et al. Concordance in histological and biological parameters between first and second primary breast cancers. Cancer, 2011,117: 907-915.

二级参考文献18

  • 1Perou CM, Srlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature, 2000, 406: 747-752.
  • 2Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res, 2004, 10: 5367-5374.
  • 3Rakha EA, E1-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer.Cancer, 2007, 109: 25-32.
  • 4Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer, 2007, 109: 1721-1728.
  • 5Dent R, Trudean M, Pritchard KI, et al. Triple-negative breast cancer:. clinical features and patterns of recurrence. Clin Cancer Res, 2007, 13: 4429-4434.
  • 6Kim M J, Ro JY, Ahn SH, et al. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her-2/neu- overexpressing phenotypes. Hum Pathol, 2006, 37: 1217-1226.
  • 7Sara M, Bando Y, Takahashi M, et al. Screening for basal marker expression is necessary for decision of therapeutic strategy for triple- negative breast cancer. J Surg Oncol, 2008, 97: 30-34.
  • 8Rodenhuis S, Bontenbal M, van Hoesel QG, et al. Efficacy of high- dose alkylating chemotherapy in HER2/neu-negative breast cancer. Ann Oncol, 2006, 17: 588-596.
  • 9Torrisi R, Balduzzi A, Ghisini R, et al. Tailored preoperative treatment of locally advanced triple negative ( hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel., Cancer Chemother Pharmacol, 2005, 62: 667-672.
  • 10Leator S, Heller W, Coombes RC. Triple-negative breast cancer:. therapeutic options. Lancet Oncol, 2007, 8: 235-244.

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部